+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bone Marrow Transplant Rejection - Pipeline Review, H1 2019

  • ID: 4772676
  • Drug Pipelines
  • May 2019
  • Region: Global
  • 653 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Cell Source Inc
  • Eli Lilly and Co
  • Inspyr Therapeutics Inc
  • MallInckrodt Plc
  • Precision Biosciences Inc
  • MORE
Bone Marrow Transplant Rejection - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2019, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 11, 34, 14, 2, 47, 6 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.

Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Cell Source Inc
  • Eli Lilly and Co
  • Inspyr Therapeutics Inc
  • MallInckrodt Plc
  • Precision Biosciences Inc
  • MORE
Introduction

Bone Marrow Transplant Rejection - Overview

Bone Marrow Transplant Rejection - Therapeutics Development

Bone Marrow Transplant Rejection - Therapeutics Assessment

Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development

Bone Marrow Transplant Rejection - Drug Profiles

Bone Marrow Transplant Rejection - Dormant Projects

Bone Marrow Transplant Rejection - Discontinued Products

Bone Marrow Transplant Rejection - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Bone Marrow Transplant Rejection, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Alpine Immune Sciences Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Amgen Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by AnaptysBio Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by apceth Biopharma GmbH, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Aptevo Therapeutics Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Athersys Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Biocon Ltd, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Biogen Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Co, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Cell Source Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Cell2B Advanced Therapeutics SA, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Cellect Biotechnology Ltd, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Cellective BioTherapy Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Cellix Bio Pvt Ltd, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Clinigen Group Plc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd, H1 2019

Bone Marrow Transplant Rejection - Pipeline by CSL Ltd, H1 2019

Bone Marrow Transplant Rejection - Pipeline by CTI BioPharma Corp, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Ltd, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Eli Lilly and Co, H1 2019

Bone Marrow Transplant Rejection - Pipeline by Elsalys Biotech SA, H1 2019

Bone Marrow Transplant Rejection - Dormant Projects, H1 2019

Bone Marrow Transplant Rejection - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Bone Marrow Transplant Rejection, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • AbGenomics International Inc
  • Alpine Immune Sciences Inc
  • Amgen Inc
  • AnaptysBio Inc
  • apceth Biopharma GmbH
  • Aptevo Therapeutics Inc
  • Athersys Inc
  • Bellicum Pharmaceuticals Inc
  • Biocon Ltd
  • Biogen Inc
  • Bristol-Myers Squibb Co
  • Capricor Therapeutics Inc
  • Cell Source Inc
  • Cell2B Advanced Therapeutics SA
  • Cellect Biotechnology Ltd
  • Cellective BioTherapy Inc
  • Cellix Bio Pvt Ltd
  • Clinigen Group Plc
  • Compugen Ltd
  • CSL Ltd
  • CTI BioPharma Corp
  • Cynata Therapeutics Ltd
  • Cytodyn Inc
  • Daewoong Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • Elsalys Biotech SA
  • enGene Inc
  • Enlivex Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Forty Seven Inc
  • Generon (Shanghai) Corp Ltd
  • GlaxoSmithKline Plc
  • Heat Biologics Inc
  • Incyte Corp
  • Inspyr Therapeutics Inc
  • ITB-Med AB
  • Jazz Pharmaceuticals Plc
  • Kadmon Corp LLC
  • Kamada Ltd
  • Kiadis Pharma NV
  • Kymab Ltd
  • LG Chem Ltd
  • MaaT Pharma
  • Magenta Therapeutics Inc
  • MallInckrodt Plc
  • Medac Pharma Inc
  • Medicenna Therapeutics Corp
  • Mesoblast Ltd
  • NapaJen Pharma Inc
  • Novartis AG
  • OncoImmune Inc
  • OSE Immunotherapeutics
  • Panorama Research Inc
  • Pfizer Inc
  • Pharmicell Co Ltd
  • Pluristem Therapeutics Inc
  • Precision Biosciences Inc
  • REGiMMUNE Corp
  • Sanofi
  • Seattle Genetics Inc
  • Seres Therapeutics Inc
  • Syndax Pharmaceuticals Inc
  • Synthetic Biologics Inc
  • Takeda Pharmaceutical Co Ltd
  • Targazyme Inc
  • TxCell SA
  • United BioPharma Inc
  • Vault Pharma Inc
  • VBI Vaccines Inc
  • Visterra Inc
  • Xenikos BV
  • XL-protein GmbH
Note: Product cover images may vary from those shown
Adroll
adroll